AbbVie’s Rinvoq Lands FDA Approval as First Oral Drug for Crohn’s Disease

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

FDA approval of blockbuster AbbVie drug Rinvoq makes it the first oral therapy for moderately to severely active Crohn’s disease. The regulatory nod is the seventh for the drug, which belongs to a class of therapies called JAK inhibitors.

Leave a Replay

Sign up for our Newsletter

Contact Us